#Tech #Biomedical #Science #Healthcare
A smart USB stick from DNA Electronics that can read for HIV levels in less than 30 minutes and needs just one drop of blood with the same ease as diabetics who check their sugar levels, has been created by scientists.
This smart USB device created by scientists in Britain and the United States detects levels of HIV in a person’s blood and sends a report to a computer. At the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result.
Dr Cooke added that this new technology could help HIV patients check their blood with the same ease as diabetics who check their sugar levels.
The researchers are also exploring whether the device could be used to test for other viruses – such as hepatitis.
Professor Chris Toumazou, the founder of DNA Electronics, the Imperial spin-out company behind the device, added: “This is a great example of how this new analysis technology has the potential to transform how patients with HIV are treated by providing a fast, accurate and portable solution.
“At DNAe we are already applying this highly adaptable technology to address significant global threats to health, where treatment is time-critical and needs to be right first time.”
The clever device, which can be read by a computer and laptop, only needs a drop of blood to diagnose the virus.
According to UPI, HIV tests just made a giant leap forward in speed and affordability. That’s because researchers have developed a screening test for HIV that uses a USB stick to process data in a move they say vastly improves upon conventional methods.
DNAe is commercialising its pioneering semiconductor DNA analysis technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling early administration of appropriate treatment.
DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. DNAe’s first product will be a diagnostic test for bloodstream infections for use in the management and prevention of sepsis. In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to $51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.
A private company, with operations in London, UK, and Carlsbad, CA and Washington, DC, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.
Read or watch more via: